Second Trial

Throughout this trial, vapor and liquid loads and physical properties are taken from Table 6.10. Tray layout parameters are discussed below and shown in Table 6.11. 

Layout. First, determine downcomer areas. The calculation in Sec. 6.5.5 shows that the area for the top section downcomers is about right On the other hand, the bottom section downcomers appear somewhat oversized. Table 6.5 suggests that for the depropanizer (high foaming tendency, 18- and 24-in tray spacing) up to 110 gpm/ft2 is an appropriate velocity. Resize the downcomer for 110 gpm/ft2. 

Now retain the number of passes, tray spacing, hole diameter, weir height, and clearance under the downcomer as per Sec. 6.5.5. 

Recalculate weir and downcomer dimensions by the same procedure as in Sec. 6.5.4. The results are summarized in Table 6.11. 

Comment Note that the length of the flow path (LFP) will restrict any further reductions in column diameter. As stated previously (Sec. 6.5.4), flow path length smaller than about 18 in is best avoided. This limit is reached in the bottom section, center-to-side flow. 

---

A second trial is required for two main flare headers, one collecting the low-pressure flares (usually 5 to 10 psig) and the other collecting relatively high-pressure flares (usually 15 to 20 psig). The two headers are connected to their individual knock-out drums. The vapor lines from the knock-out drums are combined into a single header connected to the flare stack. 

If the number of actual trays, S, calculates to be 27 or greater, then revert to the following for better accuracy Second Trial ... 

Area available in assumed unit, second trial,... 

Data summarizing the effects of the inhibitory weed extracts on sorghum water status was taken from the second trial in each case (Table V). All of these extract treatments had reduced sorghum growth, and all but one had some effect on plant water balance. 

The specific heat at this temperature is 2.05 kJ/kg°C. A second trial calculation using this value gives t2 = 77.9°C and a new mean temperature of 58.9°C. There is no significant change in the specific heat at this mean temperature from the value used, so take the crude stream outlet temperature to be 77.9°C, say 78°C. 

MLC (Meat and Livestock Commision) (1992), Stotfold Pig Development Unit Second Trial Results, Meat and Livestock Commission, Milton Keynes. 

After 10 minutes, the data collection will stop. Open the air valve on the stopper. If needed, you can run a second trial by closing the air valve and choosing 2 WES to REPEAT If you are finished, press l NO. 

Figure 5.5 Comparison of rocking curve (small squares) with second trial simulation (dashed line). The effect of adding diffuse scatter is shown by the solid line...

After making changes, a second trial run using the same blanks and standards. Again, any desired changes are made. 

Choy et al. have published two further phase II trials of concurrent paclitaxel and carboplatin. In both trials the two drugs were administered weekly with paclitaxel at a dose of 50 mg/m2 and carboplatin at a dose of 2 AUC. The first of these trials, LUN-56 (60), combined these two drugs with once daily radiation to adose of 66 Gy and the second trial, LUN-63 (61), used hyperfractionated radiation to a total dose of 69.6 Gy directed at the primary tumor. They have shown similar promising results in patient populations where 70% have stage IIIB disease. LUN-56, which enrolled40 patients, showed a 76% response rate and 1-, 2-, and 3-yr median survivals of 54,46, and 32% 43 patients were enrolled on LUN-63. In this trial there was a 79% response rate and a median survival of 14.3 mo. Encouraging 1- and 2-yr survivals of 61% and 35% were seen. 

Preclinical toxicology data justified initial development of BMS-275291 in healthy subjects. Therefore, two trials of BMS-275291 were conducted in 65 healthy male subjects. In the first trial, subjects received single doses of orally administered BMS-275291 ranging from 25 mg up to 1200 mg as a single dose. These doses were well tolerated. Therefore, in a second trial, subjects received doses escalating from 300 to 1200 mg daily for 14 d (19). Treatment was safe and very well tolerated across all dose levels. No dose-limiting adverse events were identified. 

Kenzo s parents won a new trial in 2003 because of the actions of a juror showing bias toward the gun maker. The second trial ended in a mistrial when the jury deadlocked. Finally, in 2004, a third jury found in favor of Beretta USA Corp. after a brief deliberation. 

A further 0.75 million children in other selected schools in grades one to three were to be included in this second trial. All parents were approached for their consent and those children where consent was given were randomised to receive eitherthe vaccine or a placebo injection. The trial was double-blind with parents, children and investigators unaware of who had received the vaccine and who had not. 

Few data are available to guide this decision beyond clinical experience. There is a modest amount of evidence that nonresponders to TCAs, principally desipramine or imipramine, alone may respond to a SSRI alone and vice versa (136). No compelling evidence exists showing that nonresponders to one SSRI as a result of a lack of efficacy will respond to a second trial with another SSRI. There is limited confidence in the results of studies that have been done switching nonresponders from one SSRI to another for two reasons. First, virtually all have been open label and, second, most were conducted by the manufacturer of the second SSRI. Until there is more substantive evidence that switching from one SSRI to another is worthwhile, it may be more prudent to switch to a class of antidepressants with a different putative mechanism of action. 

---